@article{JTD31611,
author = {Paul Windisch and Matthias Guckenberger},
title = {Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: another step forward on the long road of evidence-based medicine for oligometastatic disease},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 15},
year = {2019},
keywords = {},
abstract = {The term oligometastatic disease (OMD) has been coined in 1995 (1) for patients with a limited number of metastases that may be treated with a potentially curative intention. This intermediate cancer state between localized and metastatic disease was considered rare and both clinical and pre-clinical research was limited.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31611}
}